HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yasuo Terauchi Selected Research

Glucokinase

10/2021Glucokinase activation or inactivation: Which will lead to the treatment of type 2 diabetes?
1/2021Glucokinase Inactivation Paradoxically Ameliorates Glucose Intolerance by Increasing β-Cell Mass in db/db Mice.
1/2020Newer perspective on the coupling between glucose-mediated signaling and β-cell functionality.
1/2016DPP-4 inhibition improves early mortality, β cell function, and adipose tissue inflammation in db/db mice fed a diet containing sucrose and linoleic acid.
3/2015Present status of clinical deployment of glucokinase activators.
6/2014Effects of the antitumor drug OSI-906, a dual inhibitor of IGF-1 receptor and insulin receptor, on the glycemic control, β-cell functions, and β-cell proliferation in male mice.
5/2014β-Cell proliferation after a partial pancreatectomy is independent of IRS-2 in mice.
1/2007Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance.
6/2004A series of maturity onset diabetes of the young, type 2 (MODY2) mouse models generated by a large-scale ENU mutagenesis program.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yasuo Terauchi Research Topics

Disease

129Type 2 Diabetes Mellitus (MODY)
08/2022 - 01/2002
67Insulin Resistance
01/2022 - 01/2002
39Body Weight (Weight, Body)
01/2022 - 07/2002
27Obesity
07/2020 - 01/2002
20Hypoglycemia (Reactive Hypoglycemia)
01/2022 - 04/2009
18Glucose Intolerance
10/2021 - 07/2002
13Non-alcoholic Fatty Liver Disease
11/2021 - 05/2007
13Inflammation (Inflammations)
11/2021 - 09/2002
11Hyperglycemia
06/2019 - 04/2003
10Fatty Liver
11/2021 - 05/2011
9Fibrosis (Cirrhosis)
04/2015 - 03/2005
8Diabetes Mellitus
02/2021 - 09/2006
7Albuminuria
11/2021 - 10/2007
7Hyperinsulinism (Hyperinsulinemia)
07/2020 - 06/2004
6Cardiovascular Diseases (Cardiovascular Disease)
01/2022 - 10/2012
6Neoplasms (Cancer)
07/2021 - 06/2005
6Dyslipidemias (Dyslipidemia)
11/2017 - 06/2010
6Metabolic Syndrome (Dysmetabolic Syndrome X)
01/2017 - 10/2003
6Alcoholic Fatty Liver
02/2016 - 06/2010
6Hypertrophy
08/2008 - 01/2002
5Hypertension (High Blood Pressure)
04/2022 - 08/2005
5Type 1 Diabetes Mellitus (Autoimmune Diabetes)
06/2021 - 03/2017
5Carcinogenesis
02/2016 - 06/2005
5Atherosclerosis
10/2015 - 07/2002
4Heart Failure
01/2022 - 01/2016
4Weight Loss (Weight Reduction)
01/2022 - 07/2014
4Liver Diseases (Liver Disease)
12/2021 - 01/2011
4Atrophy
10/2020 - 01/2014
4Drug-Related Side Effects and Adverse Reactions
10/2020 - 01/2016
4Hyperplasia
01/2017 - 06/2004
4Insulinoma
01/2017 - 03/2009
4Hyperlipidemias (Hyperlipidemia)
01/2014 - 04/2005
3Body Weight Changes
01/2022 - 01/2015
3Hypercholesterolemia
01/2018 - 10/2008
3Coronary Artery Disease (Coronary Atherosclerosis)
01/2018 - 05/2008

Drug/Important Bio-Agent (IBA)

71Glucose (Dextrose)FDA LinkGeneric
03/2022 - 01/2003
57Insulin (Novolin)FDA Link
08/2022 - 01/2002
32LipidsIBA
09/2020 - 01/2003
22Sitagliptin Phosphate (Januvia)FDA Link
12/2019 - 01/2010
16AdiponectinIBA
09/2018 - 07/2002
15Blood Glucose (Blood Sugar)IBA
01/2022 - 04/2003
15PPAR gammaIBA
12/2008 - 01/2002
14Hypoglycemic Agents (Hypoglycemics)IBA
01/2022 - 12/2003
14Triglycerides (Triacylglycerol)IBA
02/2019 - 02/2005
13Insulin Receptor Substrate ProteinsIBA
01/2020 - 11/2002
11SodiumIBA
03/2022 - 08/2005
11Pharmaceutical PreparationsIBA
06/2019 - 04/2005
10Hemoglobins (Hemoglobin)IBA
04/2022 - 01/2014
10LDL CholesterolIBA
02/2020 - 01/2007
9LiraglutideFDA Link
08/2022 - 07/2012
9Insulin Glargine (Lantus)FDA Link
01/2022 - 03/2017
9Glycated Hemoglobin (Glycosylated Hemoglobin)IBA
11/2021 - 01/2016
9GlucokinaseIBA
10/2021 - 06/2004
8Sodium-Glucose Transporter 2 InhibitorsIBA
12/2021 - 03/2014
8ipragliflozinIBA
09/2020 - 01/2016
8miglitol (Glyset)FDA Link
02/2020 - 01/2010
8LeptinIBA
04/2011 - 01/2003
7Dipeptidyl-Peptidase IV InhibitorsIBA
08/2022 - 04/2011
7Glucagon-Like Peptide 1 (GLP 1)IBA
09/2020 - 01/2010
7oxidized low density lipoproteinIBA
02/2020 - 01/2007
6lixisenatideIBA
01/2022 - 01/2016
6CreatinineIBA
01/2021 - 02/2015
6Insulin ReceptorIBA
10/2020 - 06/2003
6CholesterolIBA
09/2020 - 09/2009
6Glucagon-Like Peptide-1 ReceptorIBA
11/2019 - 01/2014
6Pioglitazone (Actos)FDA Link
08/2017 - 09/2002
6Ezetimibe (Zetia)FDA Link
01/2014 - 09/2009
5Metformin (Glucophage)FDA LinkGeneric
08/2022 - 05/2010
5glimepiride (Amarel)FDA LinkGeneric
01/2022 - 10/2011
5CanagliflozinIBA
12/2021 - 03/2019
5Biomarkers (Surrogate Marker)IBA
12/2021 - 05/2007
5HDL CholesterolIBA
12/2021 - 01/2007
5AlbuminsIBA
01/2021 - 01/2014
56- ((4- ethylphenyl)methyl)- 3',4',5',6'- tetrahydro- 6'- (hydroxymethyl)spiro(isobenzofuran- 1(3H),2'- (2H)pyran)- 3',4',5'- triolIBA
11/2019 - 03/2014
5Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
01/2019 - 01/2012
5Hormones (Hormone)IBA
01/2018 - 07/2002
5Glucagon (Glukagon)FDA Link
10/2017 - 11/2011
5Fatty Acids (Saturated Fatty Acids)IBA
07/2011 - 01/2003
4anagliptinIBA
08/2022 - 01/2015
4Glucagon-Like Peptide-1 Receptor AgonistsIBA
08/2022 - 01/2019
4alogliptinIBA
08/2022 - 06/2013
4EnzymesIBA
07/2022 - 06/2004
4empagliflozinIBA
01/2022 - 06/2014
4semaglutideIBA
12/2021 - 01/2018
43- (8- amino- 1- (2- phenylquinolin- 7- yl)imidazo(1,5- a)pyrazin- 3- yl)- 1- methylcyclobutanolIBA
10/2020 - 06/2014
4IncretinsIBA
10/2017 - 11/2011
4LigandsIBA
04/2008 - 09/2002
4Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
12/2003 - 09/2002
3SymportersIBA
03/2022 - 02/2016
3C-Reactive ProteinIBA
11/2021 - 06/2006
3Apolipoproteins E (ApoE)IBA
01/2021 - 01/2003
3insulin degludecIBA
01/2021 - 03/2017
3IGF Type 1 Receptor (IGF 1 Receptor)IBA
10/2020 - 06/2014
3Glycoside Hydrolase InhibitorsIBA
02/2020 - 09/2009
3SteroidsIBA
06/2019 - 01/2014
3G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA
01/2019 - 01/2018
3firuglipelIBA
01/2019 - 01/2018

Therapy/Procedure

35Glycemic Control
01/2022 - 08/2007
32Therapeutics
12/2021 - 08/2007
4Injections
01/2021 - 01/2009